- ID93/GLA-SE Vaccination + BCG Challenge — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT06670755.
- Novel TB vaccine ID93/GLA-SE tested for safety and immune response in BCG-vaccinated and unvaccinated volunteers using aerosol challenge.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2. Provide preliminary immunogenicity data of this novel TB vaccine (ID93/GLA-SE). This clinical trial will apply an aerosol BCG challenge model involving 48 participants - 24 historically BCG-vaccinated volunteers and 24 BCG-naïve volunteers. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity. Conditions: Tuberculosis Interventions: ID93/GLA-SE, BCG…